Ekaterina Rebmann

Late toxicity of allogeneic stem cell transplantation for Non-Hodgkin lymphoma patients. SBST based analysis 1997-2021 and review of literature

Alexander von Werdt, Arnaud Künzi, Alan G. Haynes, Dominik Schneidawind et autres

ch, at (code pays fourni par la source)

Late Effects of Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. Swiss Cohort Analysis 1997-2021

Ekaterina Rebmann, Alexander von Werdt, Arnaud Künzi, Nathan Wolfensberger et autres

Background: despite rapid development of new highly efficient targeted and cellular-therapies, allogeneic stem cell transplantation (allo-HSCT) represents so far the only potentially curable treatment according to a longest follow-up in a setting of relapse/refractory Non-Hodgkin lymphoma (rrNHL). However, late effect (LE) issues …

ch (code pays fourni par la source)

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma

Camille Perroud, Dario Thurian, Martin Andres, Arnaud Künzi et autres

Until now, next generation sequencing (NGS) data has not been incorporated into any prognostic stratification of multiple myeloma (MM) and no therapeutic considerations are based upon it. In this work, we correlated NGS data with (1) therapy response and survival parameters in …

ch (code pays fourni par la source)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020

Helena Simeunovic, Martina Dickenmann, Mitja Nabergoj, Helen Baldomero et autres

Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint …

ch, gb, us, es (code pays fourni par la source)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better

Ekaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, Paraskevi Stakia et autres

Due to relatively high nonrelapse mortality (NRM), allogeneic hematopoietic stem cell transplantation (allo-HSCT) in non-Hodgkin's lymphoma (NHL) remains the ultimate line of treatment but the only curable approach in a setting of relapse/refractory disease. Here, we conducted a retrospective, multicenter, registry-based analysis …

ch (code pays fourni par la source)